1. Sutter, A., Amberg, A., Boyer, S., Brigo, A., Contrera, J.F., Custer, L.L., Dobo, K.L., Gervais, V., Gloienke, S., van Gompel, J., Greene, N., Muster, W., Nicolette, J., Reddy, M., Thybaud, V., Vock, E., White, A.T., and Muller, L. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. Regul. Toxicol. Pharmacol. (2013) 67(1): 39-52.
2. Jacobson-Kram, D. Contrera, J.F. Genetic toxicity assessment: Employing the best science for human safety evaluation part I: Early screening for potential human mutagens. Toxicol. Sci. 96 (2007)16-20.
3. Kruhlak, N.L. Contrera, J.F. Benz, R. D., Matthews, E. J. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Advan. in Drug Deliv. 59 (2007) 43-55.
4. McGovern, T., Jacobson-Kram, D. Regulation of Genotoxic and carcinogenic impurities in drug substances and products. Trends in Anal. Chem. 25 (2006) 790-795.
5. Contrera, J.F., Matthews, E.J., Benz, R.D. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol. 38 (2003) 243-259.
6. Contrera, J.F., Hall, L.H., Kier, L.B., MacLaughlin, P. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr. Drug Discov. Technol., 2 (2005) 55-57.
7. Contrera, J.F., Kruhlak, N.L., Matthews, E. J., Benz, R.D. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Regul. Toxicol. Pharmacol. 49 (2007) 172-182.
8. Matthews, E. J., Kruhlak, N.L., Benz, R.D., Contrera, J.F. C.A. Marchant, C. Yang. Combined use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows software to achieve high performance, high confidence, mode of action-based predictions of chemical carcinogenesis in rodents. Toxicology Mech. Methods, 18: (2008) 189 - 206.
9. Contrera, J.F., Matthews, E.J., Kruhlak, N.L., Benz R.D. In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL® QSAR software. Regul. Toxicol. Pharmacol. 43 (2005) 313-323.
10. Contrera, J.F., Matthews, E.J., Kruhlak, N.L., Benz R.D. In silico screening of chemicals for genetic toxicity using MDL-QSAR, non-parametricric discriminant analysis, E-state, connectivity and molecular property descriptors. Toxicology Mech. Methods, 18 (2008) 207- 216.
11. Muller et al., A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 44 (2006) 198-211.
12. Dobo, K.L., Greene, N., Cyr, M.O., Caron, S., Ku, W.W., 2006. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. Regul. Toxicol. Pharmacol.(2006) 44(3), 282-93.
13. Contrera, J. F. Validation of Toxtree and SciQSAR in silico predictive software using a publicly available benchmark mutagenicity database and their applicability for the qualification of impurities in pharmaceuticals. Regul. Toxicol. Pharmacol. 67 (2013) 285-293.
14. Valerio, L. G. and Cross, K.P. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities. Toxicol. Applied Pharmacol. 260 (2012), 209-221.
15. Benchmarking assessment of open source and newly released Salmonella mutagenicity (Q)SAR models for potential use under ICH M7. Stavitskaya, L., et al., Poster abstract # 2273b, Society of Toxicology Annual Meeting, Phoenix, AZ. (2014). (FDA presentation)